Johnson & Johnson (JNJ): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Johnson & Johnson ( JNJ) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.6%. By the end of trading, Johnson & Johnson rose $1.55 (1.6%) to $101.34 on average volume. Throughout the day, 8,727,683 shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 8,713,800 shares. The stock ranged in a price between $100.12-$101.50 after having opened the day at $100.56 as compared to the previous trading day's close of $99.79. Other companies within the Health Care sector that increased today were: Furiex Pharmaceuticals ( FURX), up 28.6%, Agenus ( AGEN), up 19.5%, ProPhase Labs ( PRPH), up 13.1% and AstraZeneca ( AZN), up 12.2%.

Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $282.7 billion and is part of the drugs industry. The company has a P/E ratio of 19.5, above the S&P 500 P/E ratio of 17.7. Shares are up 8.9% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, OncoGenex Pharmaceuticals ( OGXI), down 60.3%, Transition Therapeutics ( TTHI), down 12.3%, POZEN ( POZN), down 10.4% and Arrowhead Research ( ARWR), down 9.8% , were all laggards within the health care sector with Agilent Technologies ( A) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Crazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners

Cramer: Goldman's Downgrade Of J&J Is 'Questionable'

Johnson & Johnson Stock Sinks, Goldman Downgrades to 'Sell'

The Best Companies for Women

Ridiculously Weak U.S. Dollar Will Make These 10 Companies Huge Winners